Last reviewed · How we verify
Citrasate
At a glance
| Generic name | Citrasate |
|---|---|
| Also known as | Citrasate, Advanced Renal Technologies, MA #K000792 |
| Sponsor | University Hospital, Antwerp |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Citrate Dialysate on Vascular Calcification (NA)
- Safety and Efficacy of Intermittent Renal Replacement Therapy Using CITRASATE in Critically-ill Patients
- The Effect of Citrasate Dialysate on Heparin Dose in Hemodialysis (NA)
- Multi-center Study to Investigate the Effects of Citrasate® on Heparin N Requirements During Hemodialysis Treatment
- Comparison of Slow Efficiency Daily Dialysis (SLEDD) With Unfractionated Heparin Versus Citrasate in Critically Ill Patients. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Citrasate CI brief — competitive landscape report
- Citrasate updates RSS · CI watch RSS
- University Hospital, Antwerp portfolio CI